查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922933

糖尿病胰岛素帮浦市场按产品类型、技术、应用、最终用户和分销管道划分－2026-2032年全球预测

Diabetes Insulin Pumps Market by Product Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病胰岛素帮浦市场价值将达到 145.6 亿美元，到 2026 年将成长至 171.9 亿美元，到 2032 年将达到 389.1 亿美元，年复合成长率为 15.06%。

关键市场统计数据
基准年 2025 145.6亿美元
预计年份：2026年 171.9亿美元
预测年份 2032 389.1亿美元
复合年增长率 (%) 15.06%

全面了解胰岛素帮浦领域，包括治疗输送方式的创新、临床应用趋势、监管重点和商业性压力。

胰岛素帮浦市场正进入一个技术快速成熟、临床通讯协定不断演进、商业性压力不断变化的阶段。闭合迴路控制、安全无线连接和外形规格创新等技术进步，促使临床医师和糖尿病患者越来越期待更直觉、更灵敏的治疗方案。同时，医疗系统正在重新思考诊疗路径，以整合远端监测和虚拟糖尿病指导，这将对采购、培训和长期支援模式产生影响。

自动化、易用性、护理服务、报销机制和供应保障等方面的同步进步如何重新定义胰岛素帮浦的竞争要求

胰岛素帮浦市场格局正受到一系列变革性变化的重塑，这些变化共同重新定义了临床路径、设备设计重点和商业模式。自动化和演算法驱动的给药技术的进步正在加速向混合式和全封闭回路型系统的过渡，迫使製造商采用机器学习和强大的安全联锁装置。这些技术进步也带来了易用性的提升，包括更纤薄的贴片设计和可减轻患者和看护者认知负担的使用者介面。

评估2025年美国关税对供应链、筹资策略、采购谈判和製造业在地化趋势的整体影响

2025年美国关税的累积影响已对胰岛素帮浦价值链的各个环节造成了显着压力，改变了成本结构、筹资策略和策略规划。进口零件和成品的关税相关价格上涨带来了即时的商业性压力，迫使采购团队和製造商重新评估供应商合约和前置作业时间。为此，一些设备製造商正在加快关键子组件的本地化生产，寻求与免税地区的替代供应商签订合同，并努力重新设计材料清单（BOM），以便在临床可行的情况下替换受影响的零件。

提供实用且细分的观点，分析影响产品采纳和支援的各种因素，包括产品形式、控制技术、临床应用、护理环境和分销管道。

我们的细分观点提供了一个实用的框架，用于理解临床价值、应用障碍和商业性机会在产品、技术、应用、终端用户和分销管道等各个维度上的交集。按产品类型划分，我们分析了混合型、贴片型和传统型配置，重点阐述了独立式外形和与监测生态系统整合在设计权衡方面的差异。按技术划分，我们分析了闭合迴路和开放回路系统的市场。自动化和演算法控制之间的差异直接影响临床工作流程、培训需求和监管路径。按应用划分，我们分析了第1型糖尿病和第2型糖尿病市场，这两种糖尿病患者的依从性模式、合併症情况和支付方期望各不相同，从而影响了设备的选择和支持模式。

区域策略差异和执行重点（美洲、欧洲、中东和非洲、亚太地区）将决定报销、监管和分销方式。

区域趋势对策略规划至关重要，因为报销环境、监管方式和临床实践模式差异巨大。在美洲，医疗保健系统各不相同，从能够快速实施数据驱动型医疗模式的整合医疗网络，到依赖药品目录和报销决策的分散式支付方环境，不一而足。这迫使製造商制定多样化的商业策略和价值提案。在欧洲、中东和非洲地区，监管时间表和采购模式也存在差异。一些国家的医疗服务强调集中竞标和循证委託，而其他市场则依赖私人支付方和医院层级的采购决策，并优先考虑互通性和全生命週期支援。

企业策略强调平台整合、数据驱动型服务、严格的监管合规性以及供应链敏捷性，以确保永续的竞争优势。

胰岛素帮浦生态系统中的关键企业倡议表明，其关注点已从单纯的硬体转向平台差异化、策略伙伴关係和「即服务」差异化。各公司优先投资于持续血糖监测和与数位治疗平台的互通性，透过软体赋能的照护路径，强化临床价值提案并建立持久的服务关係。与云端服务供应商、远端医疗业者和临床研究网路的合作在产品蓝图中日益占据核心地位，加速了上市后证据的收集，并拓展了面向临床医生和患者的远距监测服务范围。

医疗设备製造商、支付者和医疗服务提供者在改善器材设计、强化供应链以及使商业模式与临床价值相符方面，必须采取切实可行的策略措施。

产业领导者应采取三管齐下的策略，协调产品创新、营运韧性和与支付方的合作。首先，优先考虑互通性和人性化的设计，以减轻患者的培训负担并提高产品的使用率。这意味着设计符合日常生活习惯的介面和外形，与主流血糖监测平台无缝集成，并投资于能够缩短医护人员熟练时间的培训模组。其次，将供应链韧性纳入策略规划，具体措施包括：实现零件来源多元化、寻找替代製造商以及选择性地将关键子系统的生产本地化，以降低关税波动和物流中断带来的风险。

调查方法严谨性：结合临床医生参与、技术审查、监管映射和情境分析，以检验研究结果并确保其实际相关性。

我们的研究途径结合了与临床医生、采购专业人员和设备工程师的结构化面对面交流，以及对监管文件、临床文献和政策公告的全面审查，以确保对各种见解进行可靠的三角验证。主要研究包括与内分泌学家、糖尿病专科护理师、医院药剂师和医疗系统采购负责人进行结构化访谈和圆桌讨论，以收集有关设备性能、培训负担和服务需求的实际经验。这些定性见解辅以对设备规格、软体互通性声明和已发表的临床结果的技术审查，检验功能差异和安全性特征。

整合临床、商业性和政策方面的结论，为改善患者疗效和永续的商业模式指明方向。

总之，胰岛素帮浦产业正处于关键的转折点，设备创新、服务整合和政策因素正在交汇融合，共同塑造其市场推广轨迹和商业性成功。自动化和互联互通的技术进步正在拓展治疗的可能性，但要真正实现其价值，还需要同时投资于培训、互通性、供应链韧性和可靠的实证医学证据。关税趋势和区域政策差异凸显了灵活的生产和分销模式的战略必要性，这种模式既能确保医疗服务的连续性，又能有效控制营运成本。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 糖尿病胰岛素帮浦市场（依产品类型划分）

  • 杂交种
  • 修补
  • 传统的

9. 以技术分類的糖尿病胰岛素帮浦市场

  • 闭合迴路
  • 开放回路

第十章 依应用分類的糖尿病胰岛素帮浦市场

  • 1型
  • 类型 2

第十一章 糖尿病胰岛素帮浦市场（以最终用户划分）

  • 诊所
  • 居家医疗
  • 医院

第十二章 糖尿病胰岛素帮浦市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

13. 各地区糖尿病胰岛素帮浦市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 糖尿病胰岛素帮浦市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国糖尿病胰岛素帮浦市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国糖尿病胰岛素帮浦市场

第十七章 中国糖尿病胰岛素帮浦市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Beta Bionics, Inc.
  • Cellnovo Group SA
  • CeQur Simplicity, Inc.
  • Debiotech SA
  • EOFLOW Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • Jiangsu Delfu Medical Device Co., Ltd.
  • Medtronic plc
  • Medtrum Technologies, Inc.
  • Tandem Diabetes Care, Inc.
Product Code: MRR-867BED9A9E67

The Diabetes Insulin Pumps Market was valued at USD 14.56 billion in 2025 and is projected to grow to USD 17.19 billion in 2026, with a CAGR of 15.06%, reaching USD 38.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.56 billion
Estimated Year [2026] USD 17.19 billion
Forecast Year [2032] USD 38.91 billion
CAGR (%) 15.06%

Comprehensive orientation to the insulin pump environment capturing innovations in therapy delivery, clinical adoption trends, regulatory priorities, and commercial pressures

The insulin pump landscape is entering a phase defined by rapid technical maturation, evolving clinical protocols, and shifting commercial pressures. Technological advances in closed loop control, secure wireless connectivity, and form factor innovation have raised expectations among clinicians and people living with diabetes for more intuitive and responsive therapy options. At the same time, health systems are re-evaluating care pathways to integrate remote monitoring and virtual diabetes coaching, which has implications for procurement, training, and long-term support models.

Clinicians are increasingly comfortable prescribing advanced insulin delivery devices when evidence demonstrates improved glycemic stability and user safety, and payers are scrutinizing total cost of care improvements tied to device adoption. Meanwhile, manufacturers face the dual challenge of accelerating product innovation while ensuring rigorous cybersecurity, regulatory compliance, and supply resilience. This introduction sets the stage for deeper analysis of market shifts, policy impacts, segmentation dynamics, regional patterns, competitive behaviors, and pragmatic recommendations that stakeholders can apply to operationalize improved patient outcomes and sustainable business models.

How concurrent advancements in automation, usability, care delivery, reimbursement frameworks, and supply resilience are redefining competitive imperatives for insulin pumps

The landscape for insulin pumps is being reshaped by a series of transformative shifts that together are redefining clinical pathways, device design priorities, and commercial models. Advances in automation and algorithm-driven dosing have accelerated movement toward hybrid and fully closed loop systems, pushing manufacturers to embed machine learning and robust safety interlocks. This technical progress has been accompanied by improvements in usability, with slimmer patch designs and user interfaces that reduce the cognitive load on patients and caregivers.

Concurrently, healthcare delivery is decentralizing: virtual consultations, remote monitoring, and integrated care teams mean that device manufacturers must support software ecosystems and data interoperability. Reimbursement frameworks are also evolving, increasingly emphasizing demonstrated outcomes and real-world evidence. On the supply side, resilience is now a core consideration as manufacturers diversify sourcing and consider nearshoring or strategic stockpiling to mitigate component shortages. Taken together, these shifts are driving a landscape where differentiation is less about hardware alone and more about seamless clinical integration, service provision, and long-term support infrastructure.

Assessing the aggregate ramifications of 2025 United States tariff measures on supply chains, sourcing strategies, procurement negotiations, and manufacturing localization dynamics

The cumulative effect of tariff actions in the United States during 2025 introduced measurable stressors across the insulin pump value chain, altering cost structures, sourcing strategies, and strategic planning. Tariff-related increases on imported components and finished devices created immediate commercial pressure, prompting procurement teams and manufacturers to reassess supplier contracts and lead times. In response, some device producers accelerated efforts to localize production of critical subassemblies, engage alternate suppliers in tariff-exempt jurisdictions, and redesign bill-of-materials to substitute affected components where clinically feasible.

Beyond immediate cost management, tariffs influenced contractual negotiations with distributors and health systems, with longer payment cycles and renegotiated service-level agreements becoming more common as partners absorbed transitional costs. Regulatory and policy stakeholders reacted with calls for clearer classification of medical devices to reduce tariff ambiguity and to prioritize medical supply chains in trade discussions. Over the medium term, the tariff environment incentivized investments in domestic manufacturing capability and supply chain transparency, which improved resilience but also required upfront capital and operational shifts. These dynamics underscore the importance of scenario planning, supplier diversification, and proactive engagement with procurement and policy stakeholders to mitigate disruption and ensure continuity of patient care.

Actionable segmentation-driven perspectives on product forms, control technologies, clinical applications, care settings, and distribution channels shaping adoption and support

Segmentation lenses provide a practical framework for understanding where clinical value, adoption friction, and commercial opportunity intersect across product, technology, application, end user, and distribution vectors. Based on Product Type, the market is studied across Hybrid, Patch, and Traditional configurations, revealing divergent design trade-offs between discrete form factors and integration with monitoring ecosystems. Based on Technology, the market is studied across Closed Loop and Open Loop systems, which directly influences clinical workflows, training needs, and regulatory pathways due to differences in automation and algorithmic control. Based on Application, the market is studied across Type 1 and Type 2 diabetes, each of which presents distinct adherence patterns, co-morbidity profiles, and payer expectations that shape device selection and support models.

Based on End User, the market is studied across Clinics, Homecare, and Hospitals, illuminating how procurement decisions vary with institutional capacity for training, remote monitoring, and device servicing. Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, each channel presenting different fulfillment timelines, patient education touchpoints, and reimbursement interfaces. Synthesizing these segmentation perspectives clarifies that successful commercialization hinges on aligning product design, clinical evidence generation, and post-sales service to the specific needs and constraints of targeted patient cohorts, care settings, and distribution pathways.

Regional strategic contrasts and executional priorities across Americas, Europe, Middle East & Africa, and Asia-Pacific that determine reimbursement, regulatory, and distribution approaches

Regional dynamics are critical to strategic planning because reimbursement environments, regulatory approaches, and clinical practice patterns vary significantly across geographies. In the Americas, health systems range from integrated delivery networks that can rapidly adopt data-driven care models to fragmented payer landscapes where access depends on formulary and reimbursement decisions, driving manufacturers to develop diverse commercial strategies and value dossiers. Europe, Middle East & Africa exhibits heterogeneity in regulatory timelines and procurement models, with some national health services favoring centralized tenders and evidence-based commissioning while other markets rely on private payers or hospital-level purchasing decisions that prioritize interoperability and lifecycle support.

Asia-Pacific presents a mix of mature urban healthcare ecosystems with advanced digital adoption and rapidly developing markets where affordability and distribution infrastructure are primary constraints. Across all regions, cross-border regulatory harmonization, data privacy frameworks, and local manufacturing incentives are increasingly influential, prompting device makers to tailor their device security architectures, evidence generation plans, and commercial partnerships to local policy and clinical realities. These regional contrasts underscore the need for adaptable go-to-market models that can reconcile global product strategies with localized execution requirements.

Corporate strategies emphasizing platform integration, data-enabled services, regulatory rigor, and supply chain agility to secure sustainable competitive advantage

Key corporate behaviors within the insulin pump ecosystem reveal an emphasis on platform differentiation, strategic partnerships, and services-as-differentiators rather than hardware alone. Companies are prioritizing investments in interoperability with continuous glucose monitoring and digital therapeutics platforms, which strengthens clinical value propositions and creates sticky service relationships through software-enabled care pathways. Partnerships with cloud providers, telehealth operators, and clinical research networks are increasingly central to product roadmaps, accelerating post-market evidence collection and expanding the scope of remote monitoring services offered to clinicians and patients.

In parallel, firms are investing in post-sales support models that encompass training, remote troubleshooting, and data analytics to demonstrate adherence improvements and safety outcomes. Competitive positioning increasingly relies on demonstrable cybersecurity practices, robust regulatory compliance documentation, and transparent risk management. While some companies pursue modular hardware strategies with incremental form factor improvements, others emphasize comprehensive care ecosystems that bundle devices with coaching and analytics. Corporate agility in supply chain management, regulatory responsiveness, and partner ecosystems will determine which organizations can sustain long-term clinical and commercial leadership.

Practical strategic imperatives for manufacturers, payers, and providers to enhance device design, fortify supply chains, and align commercial models with clinical value

Industry leaders should adopt a three-pronged approach that aligns product innovation with operational resilience and payer engagement. First, prioritize interoperability and human-centered design to reduce patient training burdens and enhance retention; this means designing interfaces and form factors that accommodate everyday life, integrating seamlessly with popular glucose monitoring platforms, and investing in clinician training modules that shorten time-to-competency. Second, embed supply chain resilience into strategic planning by diversifying component sources, qualifying alternate manufacturers, and selectively localizing production for critical subsystems to reduce exposure to tariff volatility and logistics disruptions.

Third, construct robust evidence-generation programs that demonstrate clinical and economic value in real-world settings, enabling clearer reimbursement pathways and stronger procurement positioning. Companies should also adopt subscription and outcomes-based commercial models where feasible to align incentives with health systems and payers. Across all initiatives, maintain stringent cybersecurity and data governance practices to protect patient information and preserve clinician trust. Finally, engage proactively with policymakers and procurement bodies to clarify device classification, support expedited reviews for life-sustaining innovations, and explore public-private approaches to strengthen device availability in constrained settings.

Methodological rigor combining clinician engagement, technical review, regulatory mapping, and scenario analysis to validate insights and ensure practical relevance

The research approach integrates systematic primary engagement with clinicians, procurement specialists, and device engineers alongside comprehensive review of regulatory filings, clinical literature, and policy announcements to ensure robust triangulation of insights. Primary research consisted of structured interviews and roundtable discussions with endocrinologists, diabetes nurse specialists, hospital pharmacists, and health system procurement officers to capture frontline experiences with device performance, training burdens, and service requirements. These qualitative insights were complemented by technical reviews of device specifications, software interoperability claims, and published clinical outcomes to validate functional differentiators and safety profiles.

Secondary research drew on peer-reviewed journals, regulatory guidance documents, and public policy statements to map the evolving compliance and reimbursement landscape, while scenario analysis was applied to stress-test supply chain and tariff-related contingencies. Throughout the study, findings were cross-validated with expert panels and iterate-refined to ensure clarity and applicability. Ethical considerations and data privacy protections were rigorously observed in all primary engagements, and conclusions were drawn conservatively to reflect confirmed evidence and practitioner experience rather than speculative extrapolation.

Synthesis of clinical, commercial, and policy conclusions indicating the pathways for achieving improved patient outcomes and durable commercial models

In conclusion, the insulin pump sector stands at a pivotal juncture where device innovation, service integration, and policy forces converge to shape adoption trajectories and commercial success. Technological progress in automation and connectivity is expanding therapeutic potential, but realizing value requires concurrent investments in training, interoperability, supply chain resilience, and robust evidence generation. Tariff dynamics and regional policy variations have highlighted the strategic necessity of flexible manufacturing and distribution approaches that can sustain continuity of care while controlling operational costs.

Strategic winners will be those organizations that pair clinical-grade device design with software-enabled care ecosystems, proactive payer engagement, and transparent regulatory and cybersecurity practices. By aligning product development with real-world clinical workflows and procurement realities, manufacturers and health systems can improve patient outcomes while creating commercially durable models. The path forward depends on disciplined execution, collaborative partnerships across the care continuum, and an unwavering focus on delivering safe, effective, and accessible insulin delivery solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Insulin Pumps Market, by Product Type

  • 8.1. Hybrid
  • 8.2. Patch
  • 8.3. Traditional

9. Diabetes Insulin Pumps Market, by Technology

  • 9.1. Closed Loop
  • 9.2. Open Loop

10. Diabetes Insulin Pumps Market, by Application

  • 10.1. Type 1
  • 10.2. Type 2

11. Diabetes Insulin Pumps Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Diabetes Insulin Pumps Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Diabetes Insulin Pumps Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diabetes Insulin Pumps Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diabetes Insulin Pumps Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Diabetes Insulin Pumps Market

17. China Diabetes Insulin Pumps Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Beta Bionics, Inc.
  • 18.6. Cellnovo Group SA
  • 18.7. CeQur Simplicity, Inc.
  • 18.8. Debiotech SA
  • 18.9. EOFLOW Co., Ltd.
  • 18.10. F. Hoffmann-La Roche Ltd.
  • 18.11. Insulet Corporation
  • 18.12. Jiangsu Delfu Medical Device Co., Ltd.
  • 18.13. Medtronic plc
  • 18.14. Medtrum Technologies, Inc.
  • 18.15. Tandem Diabetes Care, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES INSULIN PUMPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES INSULIN PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TRADITIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TRADITIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TRADITIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY OPEN LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY OPEN LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY OPEN LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY TYPE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DIABETES INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA DIABETES INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA DIABETES INSULIN PUMPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA DIABETES INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA DIABETES INSULIN PUMPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA DIABETES INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA DIABETES INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)